



MYnd Analytics, Inc. NASDAQ: MYND

June 5, 2019
Recent Price: \$1.25

Market Data

Fiscal Year	December
Industry	Health Care
Market Cap	\$15.8M
Price/Sales (ttm)	10.0x
Shares Outstanding	12.7M
Avg. Volume (3 mo.)	189,500

As of June 5, 2019

Income Statement Snapshot

	TTM
Revenue	\$1.6M
Net Income	(\$8.9M)

Company Website

<https://www.myndanalytics.com/>

Company Overview

MYnd Analytics, Inc. (www.myndanalytics.com), with its wholly owned subsidiary Arcadian Telepsychiatry Services, LLC, is a technology-enabled telepsychiatry and teletherapy company that provides enhanced access to behavioral health services, improves patient outcomes and helps lower the costs associated with behavioral health issues. The MYnd Psychiatric EEG Evaluation Registry (PEER) is a predictive analytics decision support tool that helps physicians reduce trial and error treatment for behavioral health conditions. PEER provides the physician a personalized care plan with recommended treatment options based on a patient's unique brain markers, reducing treatment time and treatment costs. Arcadian Telepsychiatry Services, LLC provides a suite of complementary telemedicine services that can be combined with PEER, including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. MYnd's customers include major health plans, health systems, and community-based organizations. To read more about the benefits of this patented technology for patients, physicians and payers, please visit: www.myndanalytics.com.

Value Proposition

MYND's telemedicine platform complimented by its behavioral health services technology addresses a combined market in excess of \$130 billion (Global Market Insights). MYND's tele-behavioral health services is now offered through the Magellan Healthcare (Fortune 500) provider network, which is concrete evidence of the power of MYND's technology and its best-in-class platform.

Additionally, in January 2019, MYND announced a merger agreement with Emmaus Life Sciences. Emmaus has developed the first FDA-approved drug for the treatment of sickle cell disease. The FDA-approved drug addresses a \$3 billion worldwide market, with more than 20 million people suffering from sickle cell disease globally. At the completion of the merger, MYND shareholders will own 5.9% of the fully diluted shares of Emmaus, and MYnd Analytics will be spun-off as an independent company, providing shareholders with upside potential in two exciting growth stories.

Investment Highlights

- **Recent Insider Buying**
 - In March 2019, MYND's Director John Pappajohn acquires 100,000 shares of MYnd Analytics, Inc stock
- **\$8 billion spent on avoidable ER visits creates substantial opportunity for telemedicine companies**
 - MYND's Arcadian Telepsychiatry delivers technology enabled mental health services through a network of licensed clinicians in all 50 states.
 - Telemedicine improves access to care for the 60% of individuals who do not currently receive care
 - Goldman Sachs estimates potential costs savings of over \$100B/year in the U.S. through telehealth



MYnd Analytics, Inc. NASDAQ: MYND

June 5, 2019
Recent Price: \$1.25

Market Data

Fiscal Year	December
Industry	Health Care
Market Cap	\$15.8M
Price/Sales (ttm)	10.0x
Shares Outstanding	12.7M
Avg. Volume (3 mo.)	189,500
<i>As of June 5, 2019</i>	

Income Statement Snapshot

	TTM
Revenue	\$1.6M
Net Income	(\$8.9M)

Company Website

<https://www.myndanalytics.com/>

- **MYnd Analytics joins Magellan Healthcare (Fortune 500 company) behavioral health provider network to offer telebehavioral health services**
 - Magellan's members now have access to telebehavioral health services from the comfort and convenience of their home using web-enabled video conferencing
- **MYnd's PEER™ Report, an FDA breakthrough technology, uses AI to analyze EEG patterns**
 - Improves patient outcomes and reduces healthcare costs
 - EEG technology determines which drug best suits a patient's profile
 - Broad patents (20 issued, 8 pending) and strong clinical validation (45 peer reviewed studies)
 - Global behavioral/mental healthcare software and services market size is expected to reach \$4.31 billion by 2025
 - More than 350 million individuals experience depression annually
- **MYnd Analytics & Emmaus Life Sciences announce merger & spin-off transaction**
 - Emmaus has the first FDA-approved drug for sickle cell disease
 - More than 20 million people suffer from sickle cell disease
 - Shareholders will own 5.9% of the fully diluted shares of Emmaus post-closing
- **Paid pilot Program with Horizon Health Services in New Jersey**
 - 600k patients suffering from behavioral health problems
 - 10% of markets share could generate ~\$36 million (\$800 per test)
- **U.S. General Services Administration awarded a five-year Federal Supply Schedule contract to MYnd Analytics**